Alternative antiviral approaches to combat influenza A virus
Tóm tắt
Influenza A (IAV) is a major human respiratory pathogen that contributes to a significant threat to health security, worldwide. Despite vaccinations and previous immunisations through infections, humans can still be infected with influenza several times throughout their lives. This phenomenon is attributed to the antigenic changes of hemagglutinin (HA) and neuraminidase (NA) proteins in IAV via genetic mutation and reassortment, conferring antigenic drift and antigenic shift, respectively. Numerous findings indicate that slow antigenic drift and reassortment-derived antigenic shift exhibited by IAV are key processes that allow IAVs to overcome the previously acquired host immunity, which eventually leads to the annual re-emergence of seasonal influenza and even pandemic influenza, in rare occasions. As a result, current therapeutic options hit a brick wall quickly. As IAV remains a constant threat for new outbreaks worldwide, the underlying processes of genetic changes and alternative antiviral approaches for IAV should be further explored to improve disease management. In the light of the above, this review discusses the characteristics and mechanisms of mutations and reassortments that contribute to IAV’s evolution. We also discuss several alternative RNA-targeting antiviral approaches, namely the CRISPR/Cas13 systems, RNA interference (RNAi), and antisense oligonucleotides (ASO) as potential antiviral approaches against IAV.
Tài liệu tham khảo
Krammer F et al (2018) Influenza. Nat Rev Dis Primers 4(1):3
Shao W et al (2017) Evolution of influenza A virus by mutation and re-assortment. Int J Mol Sci 18(8):1650
Lampejo T (2020) Influenza and antiviral resistance: an overview. Eur J Clin Microbiol Infect Dis 39(7):1201–1208
Woolthuis RG et al (2016) Long-term adaptation of the influenza A virus by escaping cytotoxic T-cell recognition. Sci Rep 6(1):33334–33334
Paget J et al (2019) Global mortality associated with seasonal influenza epidemics: new burden estimates and predictors from the GLaMOR project. J Glob Health 9(2):020421–020421
Saunders-Hastings PR, Krewski D (2016) Reviewing the history of pandemic influenza: understanding patterns of emergence and transmission. Pathogens (Basel, Switzerland) 5(4):66
Piasecka J et al (2020) RNA secondary structure motifs of the influenza A virus as targets for siRNA-mediated RNA interference. Molecular Therapy - Nucleic Acids 19:627–642
Samji T (2009) Influenza A: understanding the viral life cycle. Yale J Biol Med 82(4):153–159
Bouvier NM, Palese P (2008) The biology of influenza viruses. Vaccine 26(4):D49–D53
Costello DA, Whittaker GR, Daniel S (2015) Variations in pH sensitivity, acid stability, and fusogenicity of three influenza virus H3 subtypes. J Virol 89(1):350–360
McFadden G et al (2009) Cytokine determinants of viral tropism. Nat Rev Immunol 9(9):645–655
Cohen M et al (2013) Influenza A penetrates host mucus by cleaving sialic acids with neuraminidase. Virology Journal 10(1):321–321
Guo H et al (2018) Kinetic analysis of the influenza A virus HA/NA balance reveals contribution of NA to virus-receptor binding and NA-dependent rolling on receptor-containing surfaces. PLoS Pathog 14(8):e1007233–e1007233
Hadjichrysanthou C et al (2016) Understanding the within-host dynamics of influenza A virus: from theory to clinical implications. J R Soc Interface 13(119):20160289
Carrat F et al (2008) Time lines of infection and disease in human influenza: a review of volunteer challenge studies. Am J Epidemiol 167(7):775–785
Chong Y, Ikematsu H (2016) Effect of seasonal vaccination on the selection of influenza A/H3N2 epidemic variants. Vaccine 35(2):255–263
Petrova VN, Russell CA (2018) The evolution of seasonal influenza viruses. Nat Rev Microbiol 16(1):47–60
Dortmans JCFM et al (2013) Adaptation of novel H7N9 influenza A virus to human receptors. Sci Rep 3(1):3058–3058
Xiong X et al (2013) Receptor binding by an H7N9 influenza virus from humans. Nature 499(7459):496–499
Schrauwen E et al (2016) Amino acid substitutions that affect receptor binding and stability of the hemagglutinin of influenza A/H7N9 virus. J Virol 90(7):3794–3799
Ciminski K et al (2020) Bats reveal the true power of influenza A virus adaptability. PLoS Pathog 16(4):e1008384–e1008384
Karakus U et al (2019) MHC class II proteins mediate cross-species entry of bat influenza viruses. Nature 567(7746):109–112
McKimm-Breschkin JL (2013) Influenza neuraminidase inhibitors: antiviral action and mechanisms of resistance. Influenza Other Respir Viruses 7(1):25–36
Butler J et al (2014) Estimating the fitness advantage conferred by permissive neuraminidase mutations in recent oseltamivir-resistant A(H1N1)pdm09 influenza viruses. PLoS Pathog 10(4):e1004065
Phanich J et al (2016) Role of R292K mutation in influenza H7N9 neuraminidase toward oseltamivir susceptibility: MD and MM/PB(GB)SA study. J Comput Aided Mol Des 30(10):917–926
Hurt AC et al (2010) Assessing the viral fitness of oseltamivir-resistant influenza viruses in ferrets, using a competitive-mixtures model. J Virol 84(18):9427–9438
Kelso A, Hurt AC (2012) The ongoing battle against influenza: drug-resistant influenza viruses: why fitness matters. Nat Med 18(10):1470–1471
Abed Y et al (2014) Impact of potential permissive neuraminidase mutations on viral fitness of the H275Y oseltamivir-resistant influenza A(H1N1)pdm09 virus in vitro, in mice and in ferrets. J Virol 88(3):1652–1658
Tao H et al (2015) Influenza A virus coinfection through transmission can support high levels of reassortment. J Virol 89(16):8453–8461
Hien TT, de Jong M, Farrar J (2004) Avian influenza—a challenge to global health care structures. N Engl J Med 351(23):2363–2365
Worobey M, Han G-Z, Rambaut A (2014) Genesis and pathogenesis of the 1918 pandemic H1N1 influenza A virus. Proc Natl Acad Sci USA 111(22):8107–8112
Villa M, Lässig M (2017) Fitness cost of reassortment in human influenza. PLoS Pathog 13(11):e1006685–e1006685
Ge Q et al (2003) RNA interference of influenza virus production by directly targeting mRNA for degradation and indirectly inhibiting all viral RNA transcription. Proc Natl Acad Sci USA 100(5):2718–2723
Mehta A, Michler T, Merkel OM (2021) siRNA therapeutics against respiratory viral infections—what have we learned for potential COVID-19 therapies? Adv Healthcare Mater 10(7):e2001650
Barik S (2010) SiRNA for influenza therapy. Viruses 2(7):1448–1457
Hu Y et al (2017) Influenza A virus nucleoprotein: a highly conserved multi-functional viral protein as a hot antiviral drug target. Curr Top Med Chem 17(20):2271–2285
Michalak P et al (2019) Secondary structure of the segment 5 genomic RNA of influenza A virus and its application for designing antisense oligonucleotides. Sci Rep 9(1):3801
McMillen CM et al (2016) Inhibition of influenza A virus matrix and nonstructural gene expression using RNA interference. Virology 497:171–184
Bulbake U et al (2017) Liposomal formulations in clinical use: an updated review. Pharmaceutics 9(2):12
Rinaldi C, Wood MJA (2018) Antisense oligonucleotides: the next frontier for treatment of neurological disorders. Nat Rev Neurol 14(1):9–22
Fusco DD et al (2019) Antisense oligonucleotide: basic concepts and therapeutic application in inflammatory bowel disease. Front Pharmacol 10:305–305
Lenartowicz E et al (2016) Antisense oligonucleotides targeting influenza A segment 8 genomic RNA inhibit viral replication. Nucleic Acid Ther 26(5):277–285
Hyjek-Składanowska M et al (2020) Origins of the increased affinity of phosphorothioate-modified therapeutic nucleic acids for proteins. J Am Chem Soc 142(16):7456–7468
Freije CA et al (2019) Programmable inhibition and detection of RNA viruses using Cas13. Mol Cell 76(5):826-837.e11
Zhang K et al (2020) CRISPR/Cas13d-mediated microbial RNA knockdown. Front Bioeng Biotechnol 8:856–856
Abbott TR et al (2020) Development of CRISPR as an antiviral strategy to combat SARS-CoV-2 and influenza. Cell 181(4):865-876.e12
Lin W et al (2020) Evolution and pathogenicity of H6 avian influenza viruses isolated from southern China during 2011 to 2017 in mice and chickens. Sci Rep 10(1):20583–20583